PMV Pharmaceuticals secures orphan drug status as ovarian cancer data strengthens
PMV Pharmaceuticals (NASDAQ:PMVP) reported significant clinical momentum for its lead candidate, rezatapopt, bolstered by a fresh FDA Orphan Drug Designation and clinical results showing high response rates in late-stage ovarian cancer patients.










